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Abstract
The specific amyloid-beta (Aβ) species or other amyloid-precursor protein cleavage products that are most directly
related to human neurodegeneration and clinical dementia of the Alzheimer’s type have not yet been directly
identified. Without a clear understanding of the most relevant species, it is difficult to determine whether therapeutic
candidates successfully engaged the correct target(s). Here, we review some of the controversies regarding soluble Aβ
aggregates (also termed oligomers, dimers, trimers, Aβ*56, amylospheroids, etc.) and propose experiments designed to
move forward towards new therapeutic approaches. Specifically, we review the increasing evidence for the relevance
of non-canonical forms of Aβ, the much more potent toxicity attributable to native species than to synthetic Aβ, and
the evidence implicating the ratio of soluble Aβ aggregates to plaques in differentiating demented patients from
non-demented high Aβ plaque pathology controls. To move forward, we propose four related directions. 1)
Narrowing the focus to species derived from human Alzheimer’s disease (AD) brain tissue, as opposed to synthetic Aβ,
cell culture-derived species, or species primarily present in animal models. 2) Careful study of differences between
patients with dementia of the Alzheimer’s type vs. non-demented controls with high Aβ plaque pathology.
This will involve testing the hypothesis that, under some circumstances, plaques may buffer soluble toxic species,
but later release them into the surrounding milieu. 3) Investigations of other protein constituents of soluble Aβ
aggregates in addition to Aβ itself. Our initial data based on chemical cleavage experiments indicate that other
proteins do appear to be part of the human brain soluble Aβ aggregates. 4) Multimodal experimental assessments of
toxicity, including longer term effects on synapse loss, related deleterious cellular responses, and degeneration in
human-derived neuron-like cells. Overall, the goal is to identify specific Aβ species, other amyloid precursor protein
cleavage products, or other key proteins in aggregates present in human AD brains, less abundant in non-demented
high pathology control brains, and robustly toxic in a wide variety of relevant assays. These species themselves, the
enzymatic or cellular processes involved in their production, and their routes of clearance would be highly relevant
therapeutic targets for dementia of the Alzheimer’s type.
Keywords: Alzheimer’s disease, Dementia, Amyloid-beta, Oligomer, Plaque, Neurotoxicity, Chemical cleavage, Buffering
* Correspondence: brodyd@neuro.wustl.edu
1Department of Neurology, Washington University School of Medicine, 660
South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA
2Hope Center for Neurological Disorders, Washington University School of
Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Brody et al. Alzheimer's Research & Therapy  (2017) 9:62 
DOI 10.1186/s13195-017-0293-3
Background
The amyloid cascade hypothesis has been a mainstay of
AD research for decades [1]. The genetic evidence re-
garding familial AD has been interpreted as supporting
this hypothesis, as have many pathophysiological mech-
anistic investigations. However, the specific amyloid-beta
(Aβ) species or other amyloid-precursor protein cleavage
products that are most directly related to human neuro-
degeneration and clinical dementia of the Alzheimer’s
type have not yet been directly identified. Recent clinical
trials in humans ostensibly targeting Aβ have not been
successful at alleviating dementia [2], but without clear
understanding of the most relevant species and their in-
teractions with their cell biological milieu [3], it is diffi-
cult to determine whether these therapeutic candidates
successfully engaged the correct target(s). While there are
clearly many ways to approach the problem of Alzheimer’s
disease (AD), there is some degree of consensus surround-
ing the following three principles:
1. Genetic linkages in humans using clinical status as
the outcome measure represent the highest level of
evidence currently available regarding causal
relationships in dementia of the Alzheimer’s type.
Successful clinical trials would offer a higher level of
evidence, but as yet these have not been reported.
2. The Aβ species present in the human brain are the
most directly relevant. Synthetic, cell culture-derived,
and animal Aβ may not be composed of the most
relevant proteoforms and can take a wide variety of
aggregation states, not all of which may be present
in the human brain.
3. Synapse loss with or without more widespread
neurodegeneration is likely to play an important
role in clinical dementia. This assertion is based on
post-mortem findings in human brain indicating that
the extent of synapse loss differentiates patients with
dementia of the Alzheimer’s type from high plaque
pathology non-demented control subjects [4]. The
role of synaptic dysfunction in the absence of synapse
loss, neurochemical abnormalities, and other
pathophysiological events is not as clear, and has
not been as tightly linked to dementia of the
Alzheimer’s type.
The most compelling genetic evidence favoring a key
role for Aβ or another related amyloid-precursor protein
(APP) fragment can be briefly summarized as follows:
mutations that cause increases in amyloid precursor pro-
tein (APP) production or alterations in cleavage favoring
certain products lead to early onset dementia [5]; an
APP mutation that attenuates beta secretase cleavage of
APP prevents development of dementia [6]; an APP mu-
tation that leads to altered non-fibrillar aggregate forms
of Aβ causes early onset dementia [7]; and the genetic
polymorphisms that affect proteins involved in lipid
metabolism, innate immunity, and other physiological
functions modulate risk of dementia, but do not appear
to play a directly causal role [8].
This genetic evidence still leaves considerable room
for many alternative explanations. While Aβ plaques are
one of the key pathological hallmarks of AD, they are
not sufficient to cause dementia of the Alzheimer’s type;
many cognitively normal elderly individuals have plaques
that are as yet indistinguishable qualitatively and quanti-
tatively from those of demented patients [9–12]. Plaques
probably do play some toxic role, as there is substantial
loss of synapses and disruption of neuronal architecture
in their vicinity [13], but this could be due more directly
to soluble Aβ species related to the plaques or to
microglial processes reacting to the plaques (see below).
Furthermore, soluble Aβ monomers are also not likely
to play a central role as soluble Aβ monomers are
present in the brains of normal individuals at all ages.
Despite a great deal of controversy [14], soluble Aβ
aggregates have been the leading candidates for toxicity
directly relating to dementia in humans [15]. For ex-
ample, soluble forms of Aβ immunoreactive material
that are larger than Aβ monomers appear to be corre-
lated with dementia [16–20]. Human brain-derived Aβ
immunoreactive material larger than monomers causes
impairments in synaptic plasticity [18] and disruption of
neuronal architecture [21]. Apparently different human
brain-derived assemblies termed amylospheroids that are
reactive to specific antibodies cause neuronal cell apop-
tosis more potently than similar-sized synthetic Aβ ag-
gregates [22]. However, the precise structures of these
toxic species have not been determined. Mass spectrom-
etry has revealed peptide sequences consistent with por-
tions of Aβ, but the results are also consistent with
other amyloid precursor protein fragments and not de-
finitive enough to identify the exact species involved.
What are the characteristics of the putatively
toxic soluble Aβ aggregates?
Shankar et al. [18] observed Aβ immunoreactive species
that appeared larger than monomers and approximately
the hypothetical size of Aβ dimers (7–8 kDa on size
exclusion chromatography and SDS-PAGE gels) in
aqueous lysates from human AD brains. Preparations
containing these putative Aβ dimers caused substantial im-
pairments in long-term potentiation when applied to rodent
hippocampal slices and neuritic beading in neuronal cell cul-
ture [21]. However, mass spectrometry analyses confirmed
only a mid-domain portion of the Aβ peptide. Furthermore,
nothing in this size range is apparent using ELISA-type as-
says sensitive to species with free canonical Aβ N-termini
[23, 24]. Several alternative explanations could exist:
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1. The species is an Aβ dimer made of two non-
canonical Aβ peptides, e.g., extended, truncated, or
post-translationally modified forms. The plausibility
of this alternative is supported by the recent findings
from Portelius et al. [25–27], and our unpublished
data indicating substantial non-canonical heterogeneity
in Aβ peptide proteoforms in extracts from human
brain [28].
2. The species is a non-canonical Aβ peptide stably
linked to another molecule that increases its size.
Such species have not yet been identified in human
brain, but appropriate methods to identify them are
lacking.
3. The species is a new amyloid-precursor protein
fragment with Aβ mid-domain immunoreactivity
but N-terminal and/or C-terminal extensions. Recent
evidence for the existence of toxic species in cell
culture systems lends plausibility [29–31], but such
species in soluble form have not yet been definitively
identified in human brain to our knowledge. This is an
area that warrants further exploration.
4. The species is a canonical Aβ peptide stably linked
to another molecule that increases its size. This
initially seems unlikely given that the HJ5.1- HJ3.4
ELISA should detect such species if they are present.
However, the other molecule could obstruct the
binding of either of the antibodies used in ELISA,
even under denaturing conditions.
Less likely explanations include:
5. The species is a bona fide Aβ dimer made of two
canonical Aβ peptides. This seems unlikely given
that we and others have not observed a species of
this size using sensitive ELISAs that should detect
such species. The ELISAs use HJ3.4 and 82E1,
antibodies that recognize the free N-terminus of
canonical Aβ to both capture and detect Aβ.
6. The species is an Aβ dimer made of one canonical
Aβ peptide and one non-canonical Aβ peptide. This
seems unlikely given that we and others have not
observed a species of this size using a sensitive
ELISA that should detect such species. The ELISA
uses a mid-domain antibody HJ5.1 to capture and
the canonical N-terminus-specific antibody HJ3.4 to
detect.
7. The species is an N-terminal canonical but
C-terminally extended amyloid-precursor protein
fragment. This seems unlikely given that the
HJ5.1- HJ3.4 ELISA should detect such species if
they were present.
Noguchi et al. [22] reported toxicity of a larger
(~150 kDa) species termed amylospheroids derived from
human AD brains. These amylospheroids caused apoptosis
of mature cultured neurons but not immature neurons or
non-neuronal cells. The target appears to be the Na-K
ATPase [32]. Matrix-assisted laser desorbtion/ionization
(MALDI) mass spectrometry indicated that amylospheriods
appear to contain species at the expected molecular weights
of Aβ1-40 and Aβ1-42, but more precise methods such as
tandem mass spectrometry that can definitively identify the
Aβ species were not performed. Again, many possibilities
exist for the identities of the amylospheroid structures.
Lesne et al. reported an approximately 56 kDa species
that appears to play a key pathophysiological role in
some transgenic mouse models [33] but instead appears
inversely related to dementia in humans [34].
In our studies, the soluble Aβ aggregates from human
AD brain were predominantly very high molecular
weight, eluting close to the void volume of a Superdex
200 size exclusion chromatography column (>670 kDa
based on globular protein standards) [23, 24]. Mass
spectrometry analyses of partially purified high molecu-
lar weight soluble Aβ aggregates revealed full length Aβ
sequences [23] as well as many other non-canonical
forms of Aβ [28]. As of yet, however, we have not
detected specific toxicity of these larger aggregates
(unpublished data).
Thus, it appears likely that several discrete types of
soluble Aβ aggregates are present in the human brain
which may exert different types of toxicity. However,
none of the previously reported soluble Aβ aggregate
species were assessed explicitly in high plaque pathology
non-demented controls, so it is unclear if their con-
centrations correlate with Aβ plaques or correlate with
dementia of the Alzheimer’s type. Furthermore, none
of these species have been sufficiently purified to allow
accurate structural characterization. Thus, apart from
proprietary conformational-specific antibodies, there are
no generalizable leads for constructing pharmacodynamic
assays or developing targeted therapeutics.
Relationship between soluble Aβ aggregates and
plaques
We reported in 2013 that the concentration of soluble
Aβ aggregates from patients with dementia was higher
than the concentration of soluble Aβ aggregates from
control subjects with indistinguishable plaque burden
but no dementia. The ratio of soluble Aβ aggregate
concentration to plaque area fully distinguished these
two groups of subjects, with no overlap between groups
(Fig. 1, reproduced from Figure 2N of reference [24]).
These quantitative measurements were made using an
ELISA involving the same N-terminal-specific anti-Aβ
antibody to capture and detect, which provided >10,000-
fold specificity for soluble aggregates over monomeric Aβ.
Spiking soluble monomeric Aβ into the buffer along with
brain tissue from plaque-free controls did not result in
any detectable soluble Aβ aggregates. The distinction
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between the ratios of soluble aggregates to plaque burden
in tissue from patients with dementia vs. tissue from high
plaque non-demented controls was confirmed after repli-
cation in a separate cohort. Measurements of overall levels
of soluble Aβ (monomeric and soluble aggregates) did not
reveal any differences between groups, further indicating a
specific relationship with soluble Aβ aggregates.
The interpretation of our findings involving non-
demented high plaque pathology controls and patients
with dementia, however, is not entirely clear. We and
others [35] hypothesized that initially plaques may serve
as a reservoir or sink for toxic soluble Aβ aggregates,
sequestering them away from other targets in the extra-
cellular space and thereby preventing their toxicity. We
posit that over time the reservoir is saturated or loses
capacity and the toxic soluble Aβ aggregates become
free to diffuse and bind other targets, exerting toxicity
and causing dementia. At later stages, the plaques satu-
rated with toxic soluble Aβ aggregates serve as sources
releasing soluble Aβ aggregates into the surrounding
area and causing a gradient of toxicity to synapses. Sup-
port for the idea that plaques can serve as a source of
toxicity is provided by the observations of Koffie et al.
[13, 36]. They analyzed synapse density as a function of
distance from plaques in human AD brains. They found
a steep gradient with substantial loss of both pre- and
post-synaptic markers near plaques but normal levels
>50 microns away (Fig. 2, reproduced from Figure 1F
of reference [13]). Interestingly, binding of the antibody
NAB61, which recognizes a subset of soluble Aβ aggre-
gates, was also found in a gradient around plaques but the
NAB61 gradient decayed over ~20 microns, suggesting
that either NAB61-negative species may be playing a role,
or that concentrations of the NAB61-positive species were
below the limit of detection at greater distances.
The plaque buffering of soluble Aβ aggregates
hypothesis
As stated above, a longstanding hypothesis has been that
plaques may buffer soluble Aβ aggregates, protecting
neuronal structures from toxicity at early times and then
releasing toxic aggregates at later times. The concept
of plaque buffering is meant to indicate a generalized
Fig. 1 Ratio of soluble Aβ aggregate levels to plaque area fully
distinguishes non-demented controls with high plaque pathology
from patients with dementia of the Alzheimer’s type and comparable
plaque burden. Reproduced from Figure 2N of Esparza et al. 2013 [24].
Soluble Aβ aggregate levels expressed as dimer equivalents (pg/ml).
Clinical dementia rating (CDR) of 0 indicates absence of dementia and
rating of 1 indicates mild/early dementia. ***p = 0.0001, Mann–Whitney
U test
Fig. 2 Loss of synapses in human Alzheimer’s disease brain as a
function of distance away from plaques. PSD95 is a post-synaptic
marker, and synapsin is a presynaptic marker. *Post hoc Wilcoxon
p < 0.05. Reproduced from Figure 1F of Koffie et al. [13]
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functionality. Direct binding and unbinding of soluble
aggregates to the plaques themselves would be the
most straightforward mechanism, but binding and
unbinding to peri-plaque elements such as dystrophic
neurites, microglia, and astroctyes would be function-
ally equivalent. There has been a great deal of interest
in specific microglial and astroglial phenotypes in-
duced in the vicinity of plaques [37, 38], and these
specific phenotypes could play a role in plaque-related
soluble Aβ aggregate buffering capacity. Furthermore,
it could be the plaques, the soluble aggregates, or both
that change over time.
We propose the following line of investigation to test
the plaque buffering hypothesis:
1. Develop methods to quantitatively purify relevant
soluble Aβ aggregates from human brain.
2. Develop methods to label human brain soluble Aβ
aggregates without disrupting their functional
properties.
3. In a 2 × 2 design, test the binding of labeled soluble
Aβ aggregates isolated from human CDR0 (non-
demented) + plaque brains vs. those isolated from
CDR1 (demented) + plaque brains on frozen (not
fixed) slices from CDR0 + plaque vs. CDR1 + plaque
brains. This would allow testing of three specific
sub-hypotheses:
(a)Key prediction of the sub-hypothesis that qualitative
changes in the soluble Aβ aggregates correlate
with dementia: The soluble Aβ aggregates from
demented patients would bind to plaques less avidly
than soluble Aβ aggregates from non-demented
controls (Fig. 3a).
Soluble Aβ aggregates





Strong buffering Weak buffering
CDR1 (demented) Strong buffering Weak buffering
(b)Key prediction of the sub-hypothesis that qualitative
changes in the plaques correlate with dementia:
The plaques from non-demented controls would
retain more buffering capacity than the plaques
from demented patients (Fig. 3b).
Soluble Aβ aggregates
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(c)Key prediction of the sub-hypothesis that
quantitative changes in the soluble Aβ aggregates
correlate with dementia: The intrinsic buffering
properties of soluble Aβ aggregates and plaques
from non-demented controls are similar to those
of demented patients when assessed using the
same concentrations of soluble Aβ aggregates
(Fig. 3c).
Soluble Aβ aggregates
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It is possible that there could be a mixed result:
qualitative changes in plaques, and qualitative changes
in soluble aggregates, and quantitative changes in soluble
aggregates could correlate with dementia. This would be
difficult to fully interpret. A null result is also possible:
plaques do not buffer soluble Aβ aggregates. This could
indicate a limitation of the methods used or indicate that
plaque buffering does not play a major role.
The strong buffering presumes that the endogenous
soluble Aβ aggregates associated with the slices have
been largely washed out during the preparation of the
slices for binding studies. Recent unpublished results
from Dominic Walsh’s group indicate that at least some
species of endogenous soluble Aβ aggregates do in fact
diffuse out of minced tissue (personal communication).
The readily diffusible species may represent only a subset
of the soluble Aβ aggregates extracted during tissue
homogenization.
A technical hurdle will involve labeling the isolated
endogenous aggregates without interfering with their
binding characteristics. Biotinylation, tritiation, and
iodination of N-terminal residues, C-terminal residues,
or tyrosine residues could be considered. Competition
with unlabeled endogenous aggregates would be an ap-
propriate control to assess the relative binding affinity of
labeled vs. unlabeled aggregates. If the labeling protocol
alters the characteristics of the endogenous soluble Aβ
aggregates, the affinity of binding vs. the affinity of com-
petition would be different. If the affinity of binding and
the affinity of competition are found to be similar, this
would indicate that the labeling does not markedly alter
the endogenous soluble Aβ aggregates. At the same time
that plaque buffering capacity is being tested, the en-
dogenous labeled aggregates could also be tested for la-
beling to other structures such as synapses, microglia,
astrocytes, and blood vessels. This could either confirm




Fig. 3 Alternative versions of the plaque buffering of soluble Aβ aggregate hypothesis. The overall hypothesis states that plaques may buffer
soluble Aβ aggregates, protecting neuronal structures from toxicity at early times and then releasing toxic aggregates at later times. a Sub-hypothesis
that qualitative changes in the soluble aggregates correlate with dementia: The soluble aggregates from non-demented controls could be readily
buffered by plaques, but the soluble aggregates from demented patients would not be well buffered by plaques. b Sub-hypothesis that qualitative
changes in the plaques correlate with dementia: The plaques from non-demented controls would retain more buffering capacity than the plaques
from demented patients. c Sub-hypothesis that quantitative changes in the soluble Aβ aggregates correlate with dementia: The intrinsic buffering
properties of soluble Aβ aggregates and plaques from non-demented controls would be similar to those of demented patients when assessed
using the same concentrations of soluble Aβ aggregates. (Original figure: D. Brody)
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or refute the relevance of the observation that synthetic
Aβ oligomers bind specifically to synapses [39].
The results of these experiments will direct the critical
next steps: If qualitative changes in the soluble Aβ
aggregates correlate with dementia, an extensive search
for the structural differences between soluble Aβ
aggregates from controls without dementia vs. soluble
Aβ aggregates from patients with dementia would be well
justified. Biochemical purification and mass-spectrometric
characterization could be appropriate methods. Top-down
(undigested) proteomic methods could be used to identify
and quantify the specific proteoforms of Aβ in the
aggregates from demented vs. non-demented controls
[40]. The enzymes responsible for putative truncations
and post-translational modifications that correlate best
with dementia would be logical targets for new thera-
peutics. Bottom-up proteomics (following enzymatic di-
gestion) could be used to identify other proteins closely
associated with soluble Aβ aggregates from patients with
dementia but not associated with soluble Aβ aggregates
from non-demented controls. Such co-associated proteins
could also be drug targets if they confer or contribute to
toxicity. Aβ is amphipathic and could interact with specific
lipids, altering its conformation and hypothetically also
its toxicity. Mass spectrometry-based lipidomic analyses
could be used to identify differentially associated lipids in
an analogous manner [41]. The enzymatic processes re-
sponsible for the specific lipid synthesis or modification
could similarly be drug targets. If, on the other hand,
qualitative changes in the plaque buffering capacity correl-
ate with dementia, analysis of the structural determinants
in the plaques would be indicated. If qualitative changes
are not found in either the plaque buffering capacity or
the soluble aggregates themselves, and quantitative differ-
ences are implicated, the logical next direction would be
to evaluate the mechanisms implicated in the rates of pro-
duction and clearance of the soluble aggregates.
We envision a scenario in which Aβ production and
accumulation are left to proceed (no beta or gamma
secretase inhibitors, no immunotherapy), but an enzyme
responsible for conversion of a less toxic form of soluble
Aβ to a more toxic form is inhibited. The patients,
hopefully, would live long lives with brains full of benign
plaques but no dementia of the Alzheimer’s type.
Are other proteins part of the soluble Aβ
aggregate complexes?
Our initial mass spectrometry data from partially purified
Aβ aggregates from human AD brain has indicated that
many other proteins are present in these preparations
in addition to Aβ (not shown). It could be, of course,
that these are impurities that are nonspecifically co-
immunoprecipitated. It is also possible that they are
true components of the high molecular weight soluble
aggregates, which would then be best described as
hetero-oligomeric or multicomponent aggregates. This
is not an easy question to address using biochemical
purification methods alone; the conditions required to
obtain very high specificity during the immunoprecipi-
tation may also break up true non-covalent aggregates.
An orthogonal approach, upon which we have begun to
embark, is to degrade other proteins in a fashion which
does not affect Aβ and then ask what effects this has
on the size forms of soluble Aβ aggregates from human
AD brain (Fig. 4). If the immunoprecipitation pulls
down pure Aβ aggregates as well as other proteins that
are not part of the same complex, such degradation
should not change the size of the Aβ aggregates. On
the other hand, if the Aβ aggregates contain other proteins
which can be degraded, the Aβ aggregates should shift to-
wards smaller size forms. The amino acid composition of
Aβ1-42 peptides includes only 16 out of the 20 common
amino acids (Fig. 4a). However, we were not able to find
proteolytic enzymes that would be expected to have the
desired broad cleavage of other proteins but no effects on
Aβ. Proline endopeptidase, for example, can carry out
non-specific cleavage at other amino acids [42]. Therefore,
we instead turned to the chemical degradation literature
and found the following chemical cleavage candidates:
2-nitro-5-thiocyanatobenzoic acid (NTCB) has been
widely used to cyanlyate and cleave proteins N-terminal
of cysteine [43–47]; 5-5′-dithio-bis-(2-nitrobenzoic
acid) (DTNB) also cleaves proteins N-terminal of
cysteine, though less efficiently than NTCB [44, 46];
N-chlorosuccinimide (NCS) cleaves C-terminal of
tryptophan, usually at acidic pH with urea, as the
efficiency becomes much lower at neutral and alkaline
pH (acidic conditions are known to affect the aggregation
state of Aβ, so this was felt to be less optimal [44, 48]);
iodosobenzoic acid also cleaves C-terminal of tryptophan
at acidic pH [49]; hydroxylamine cleaves between aspara-
gine and glycine, but its efficiency is typically low.
After considerable optimization of conditions, we
determined that chemical cleavage using NTCB following
cysteine reduction by dithiothreitol (DTT) would be
feasible. Control proteins containing at least one cysteine
were readily cleaved, whereas synthetic Aβ was not
(Fig. 4b). To test whether DTT and NTCB can interfere
with the soluble Aβ aggregate assay, the assay was
performed on each fraction, either without Aβ dimer
standard or with Aβ dimer standard at final concentration
of 400 pg/mL. In the absence of any Aβ or other proteins,
fractions 21 to 25 with DTT and NTCB showed very weak
false positive signals but no effects in fractions 7–20
where Aβ would be expected. When Aβ dimer standard at
final concentration of 400 pg/mL was added to each
fraction, a significant loss of Aβ dimer standard signal was
detected from fractions 20 to 25. The loss of Aβ dimer







Fig. 4 (See legend on next page.)
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standard signal was likely due to two factors: 1) the
reduction and digestion of the IgGs used for the ELISA by
DTTand NTCB, as shown in Fig. 4b; 2) direct digestion of
the synthetic mutant Aβ dimer standard, which was
produced using Aβ1-40S26C containing cysteine in place of
serine 26 to produce a disulfide cross-linked dimer. Most
importantly, though, these results indicate that DTT and
NTCB together have no effect on the soluble Aβ aggregate
assay within the range of the high molecular weight Aβ
aggregates in fractions 7 to 10. Thus, these chemicals
caused some artifacts in the very low molecular mass
region, but not in the higher molecular weight regions
where soluble Aβ aggregates would be expected to be
found after size exclusion chromatography (Fig. 4c, d).
In advance, we specified three possible non-mutually
exclusive quaternary structural hypotheses (Fig. 4e). In
the first hypothesis, the soluble Aβ aggregates consist of
Aβ monomers bound to other proteins but not attached
to each other. After digestion of other proteins, the
soluble Aβ aggregate ELISA signal would be expected to
be lost. In the second hypothesis, the large soluble Aβ
aggregates consist of smaller Aβ aggregates in complex
with other proteins. After digestion of other proteins,
the soluble Aβ aggregates would be expected to decrease
in size. In the third hypothesis, the soluble Aβ aggregates
consist only of Aβ and any other proteins detected in
immunoprecipitation–mass spectrometry may be con-
taminants. After digestion of other proteins, soluble Aβ
aggregates would be expected not to change. Our results
were most consistent with a combination of the second
and third hypotheses (Fig. 4f ). Specifically, after DTT
and NTCB cleavage, there was residual soluble Aβ ag-
gregate ELISA signal in the high molecular weight range
(fractions 7–9) as well as the appearance of new size
forms in fractions 10–15. Thus, the most likely inter-
pretation of these results is that at least some of the na-
tive human brain soluble Aβ aggregates include other
proteins besides Aβ.
(See figure on previous page.)
Fig. 4 Cysteine cleavage of AD patient-derived Aβ aggregates and predicted structural models of Aβ aggregates. a Primary sequence analysis of
Aβ1-42. Cysteine, proline, threonine, and tryptophan are not present within the 42 residues. b Protein fragmentation using 2-nitro-5-thiocyanatobenzoic
acid (NTCB). In this study, proteins were pre-treated with 5 mM dithiothreitol (DTT) for 30 minutes at room temperature (RT) to reduce cysteine thiols.
NTCB at final concentration of 5 mM was then added to cyanylate proteins at cysteine residues for 4 h. After cyanlyation, 2 mM NaOH was used to
adjust pH to 9, resulting in cleavage N-terminal to cysteines. The reaction was allowed to proceed for 16 h at RT. The NTCB fragmented proteins were
then used for downstream applications directly. (i) SDS-page gel analysis of reduced NTCB fragmented proteins. The positive control bovine serum
albumin (BSA) and immunoglobulin G (IgG) proteins known to contain cysteine residues were fragmented by NTCB successfully, as indicated by the
change from non-cleaved (NC) to cleaved (CL). The negative control synthetic monomeric Aβ1-42 was not fragmented by NTCB due to the absence of
cysteine. The majority of proteins in AD patient-derived brain lysate were successfully fragmented by NTCB. (ii) Western blot analysis of synthetic Aβ1-42
before and after digestion showed no significant difference in size or band intensity. c Size exclusion chromatography profiling of total protein and
soluble Aβ aggregates from an AD patient using Superdex 200 column. AD patient-derived brain lysate (1 mL) was separated by Superdex 200 column.
An ELISA-based soluble Aβ aggregate assay [23] was then used to assess for soluble Aβ aggregates in each fraction. High molecular weight soluble Aβ
aggregates were detected in fractions 7 to 10, with the estimated size larger than 670 kDa. d Size exclusion chromatography and soluble Aβ aggregate
assay profiling of DTT and NTCB alone. DTT and NTCB were added to sample buffer and incubated as described above. DTT and NTCB (1 mL) in sample
buffer without any protein was separated using a Superdex 200 column. DTT and NTCB were distributed from fractions 20 to 25, consistent with low
molecular weight chemicals (molecular weights of DTT and NTCB are 154.25 and 224.19 g/mol, respectively). AβS26C dimer standard was then added to
each fraction at a final concentration of 400 pg/mL. There was loss of Aβ dimer standard signal in fractions 20 to 25 but no effect on other fractions.
e Simplified models of Aβ aggregates and potential outcomes after DTT and NTCB treatment. Model (i): more than one Aβ monomer binds to a
protein complex specifically or nonspecifically. In this case, after a successful cleavage N-terminal to cysteine residues with NTCB, the protein complex
core will be fragmented into numerous small protein fragments and peptides with no more than one Aβ monomer attached to each fragment/
peptide. This would result in loss of signal on the soluble Aβ aggregate assay. Model (ii): one or more low molecular weight Aβ aggregates
attach to a protein complex core specifically or nonspecifically, similar to model (i). However, after successful cleavage of cysteine using NTCB,
low molecular weight Aβ aggregates attached to smaller protein fragments or peptides can still be detected by the soluble Aβ aggregate assay.
Therefore, lower molecular weight Aβ aggregates are expected after a NTCB treatment in model (ii). Model (iii): numerous Aβ monomers aggregate
and form a high molecular weight Aβ complex without other proteins. In this case, Aβ aggregates will not be fragmented by NTCB due to the absence
of cysteine residues. Therefore, Aβ aggregates will show no change before and after NTCB treatment. f Size exclusion chromatography profiling of AD
patient-derived soluble Aβ aggregates before and after DTT and NTCB treatment, and predicted structure of AD patient-derived soluble Aβ aggregates.
(i) AD patient-derived Aβ aggregate were treated with DTT alone or with DTT followed by NTCB as described above. As shown in (i), DTT alone has no
detectable effect on soluble Aβ aggregates; after the treatment with DTT and NTCB, however, the soluble Aβ aggregate assay detected a change in
the size distribution of the soluble Aβ aggregates ranging from fraction 7 (>670 kDa) to fraction 16 (approximately 44 kDa). There was a potential false
positive signal in fractions 21 to 23 as described above for d. The partial cleavage of AD patient-derived soluble Aβ aggregates is most consistent with
a more complex structure compared with the three simplified models described in e. (ii) Hypothetical structure of soluble Aβ aggregates. After DTT
and NTCB treatment, high molecular weight soluble Aβ aggregates appear to have been partially fragmented into various sizes of smaller Aβ
aggregates, indicating that proteins with cysteine residues are present in at least some of the soluble Aβ aggregates. The detectable smaller
aggregates could contain various types of non-cleavable high molecular weight proteins (or protein fragments) with more than one Aβ
monomer attached, or the smaller aggregates could be pure Aβ. Importantly, we cannot determine the extent to which the DTT and NTCB
fully cleaved all cysteine-containing proteins. Thus, the continued detection of some high molecular weight soluble Aβ aggregates does not
necessarily indicate that these species consist only of Aβ. (Original figure: H. Jiang and D. Brody)
Brody et al. Alzheimer's Research & Therapy  (2017) 9:62 Page 9 of 13
Moving forward
Our proposal for moving forward involves assessing the
characteristics of the most toxic species present in human
brain from patients with dementia of the Alzheimer’s type.
The species should correlate with dementia, i.e., they
should not be present or occur at lower concentrations in
otherwise similar non-demented controls with Aβ plaque
pathology. The characterization of the species could start
with sensitive immunoassays based on a variety of anti-
bodies to assess the N-terminal extended region, canonical
N-terminus, mid-domain, canonical C-terminus, and C-
terminal extended regions. We should not assume that
they consist of canonical Aβ; many other non-canonical
species with substantial aggregation potential and toxicity
have been reported [25, 50–52]. ELISAs using the same
antibody to capture and detect will be useful for distin-
guishing dimeric or higher order soluble aggregated
species from larger monomeric (e.g., N-terminal or C-
terminal extended) species. Mid-domain antibody to
both capture and detect Aβ may be more sensitive and
more appropriate than ELISAs using the same canon-
ical N-terminus recognizing antibodies; non-canonical
forms of Aβ would not be detected by the assays of the
type we and others have used previously. Of note, the
commercially available oligomer ELISA kit uses the
antibody 82E1, which recognizes the free N-terminus
of canonical Aβ to both capture and detect and thus
suffers from the same “blind spot”. Importantly, detection
of a specific species is not sufficient; it should also be
determined whether immunodepletion with a specific
antibody alleviates toxicity. For example, in Shankar et
al. [18], the authors showed that the fractions from AD
brain that impaired long-term potentiation had immu-
noreactivity with antibodies recognizing canonical C-
terminal domains. Interestingly, co-administration with
3D6, an antibody recognizing the canonical N-terminus of
Aβ, alleviated the impairment of long-term potentiation
whereas co-administration with 2G3 and 21 F12, recogniz-
ing the canonical C-terminal 40 and 42 termini, did not al-
leviate the impairment of long-term potentiation. Multiple
species with similar size may be present in the same frac-
tions (e.g., several different types of dimers or a mixture of
dimers and N- or C-terminal extended species as have
been reported in the supernatants from cultured 7PA2
cells or some transgenic mice [29, 31, 53]). Notably,
unfractionated 7PA2 cell supernatants are approximately
an order of magnitude more potent in inhibiting a sen-
sitive test of cognitive performance in rats than Aβ
dimer-enriched or trimer-enriched fractions of 7PA2
cell supernatants [54] (Fig. 5; reproduced from Reed et
al. 2011, Figure 4 [54]). Thus, it is possible that an as-
yet-uncharacterized species is the primary determinant of
behavioral impairment in this system. The relative stability
of the species during toxicity assessments should be
Fig. 5 Effects of diverse forms of soluble Aβ aggregates on cognitive performance after intracerebroventricular injection in rats. Reproduced from
Figure 4 of Reed et al. [54]. Perseveration errors refer to effects on alternative lever cyclic ratio testing after training to a stable baseline performance.
Total Aβ was measured by western blotting with a mixture of Aβ40- and Aβ42-specific antibodies. Unfractionated 7PA2 cell lysates (7PA2 DEC) were
more potent than fractionated lysates, synthetic oligomers, or species isolated from transgenic Tg2576 mice [33, 61]
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directly assessed. It is possible that assembly, disassembly,
or modification of the species could be occurring during
the toxicity assays and could alter the toxicity. Critical
controls required will include ruling out the possibility
that the toxic species form during the extraction and puri-
fication process due to assembly or disassembly [23, 55].
There may be more than one major class of toxic
soluble Aβ aggregates. Liu et al. [56] proposed that there
are at least two, type 1, which are not closely associated
with plaques, and type 2, which are abundant and
plaque-associated but not toxic. These categorizations
were based on findings in transgenic mice, however, and
the extent to which analogous relationships hold in hu-
man brain has not been well-defined. Taking the results
from multiple labs cited above together, it appears likely
that there are more than two types of soluble Aβ aggre-
gate in human brain. Interestingly, however, various size
forms may interconvert under some circumstances. Yang
et al. [55] reported recently that incubation of high mo-
lecular mass relatively non-toxic soluble Aβ aggregate in
alkaline ammonium acetate converts them into smaller,
more toxic forms. We reported a similar phenomenon
as a potential explanation for why size exclusion chro-
matography in ammonium acetate appeared to give
different results to size exclusion chromatography in
pH 7.4 saline solutions [23]. Whether this interconver-
sion occurs physiologically in the human brain has yet
to be determined.
A critical question in the field is which in vitro or in vivo
model system best recapitulates the key aspects of
neurodegeneration underlying dementia of the Alzheimer’s
type. The mainstay of investigations into neurodegenerative
effects have involved assessments of cell and synapse
loss in rodent neuronal cell culture systems, effects on
synaptic plasticity and structure in rodent brain slices,
and behavioral and morphological assessments in animal
models. None of the typical toxicity assays involve human
cells. De Strooper’s group recently demonstrated that
human induced pluripotent stem cell (IPSC)-derived
neurons were more susceptible to degeneration than
mouse IPSC-derived neurons when transplanted into the
brains of APP transgenic immunodeficient mice [57]. This
system, and the organoid human IPSC-derived system
from the Tanzi lab [58], may represent important, though
relatively modest, throughput, avenues for toxicity assess-
ments of human brain-derived soluble Aβ aggregates. The
question of temporal scale is also salient. How can neuro-
degenerative processes proceeding over decades be accur-
ately modeled on an experimentally tractable timeline?
Proof-of-concept longer timeline experiments compared
mechanistically with shorter timeline experiments using
higher concentrations of candidate brain-derived toxic
species could be informative. Injection of candidate
human brain-derived species into non-human primate
brain for assessment of synapse loss, as has been done
with synthetic species [59], could also be very useful
as proof-of-concept. Non-human primate studies are
clearly not feasible for screening and other assessments re-
quiring moderately high throughput.
Once the characteristics of the most toxic species
present in human AD brain have been determined,
quantitative methods for tracking the species during
purification should be employed; an ELISA or similar
relatively high throughput assay would be most
appropriate. Quantitative bookkeeping should be used to
ensure that the purified species represent the predominant
species, rather than a small minority species that is
selectively enriched. Then, after purification, high
resolution tandem mass spectrometry could be used
to specifically identify non-canonical forms of Aβ [60],
N-terminal extended peptides, C-terminal extended
peptides, and other co-associated molecules.
Conclusions
Looking forward into the future, if one or more human
brain toxic species can be specifically characterized, a
critical next step will be to develop pharmacodynamic
assays for use in human patients. With good
pharmacodynamic assays, quantitative assessment of
target engagement in early phase clinical trials can be
performed to guide dosing in human patients. Without
good pharmacodynamic assays, it will be impossible to
tell whether candidate therapeutics actually cross the
blood–brain barrier and engage the target. In our view,
none of the failed clinical trials in AD have compellingly
demonstrated target engagement, irrespective of the
question of whether they were targeting the right target.
Thus, while some have stated that the amyloid hypothesis
is on its last legs, it may be more correct to state that it
has not yet been sufficiently tested.
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